New shot for teen hay fever? early trial underway

NCT ID NCT07617324

Not yet recruiting Symptom relief Sponsor: Chengdu Kangnuoxing Biopharma,Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests the safety of stapokibart injection in 15 teenagers aged 12-17 with seasonal allergic rhinitis (hay fever). Participants receive the drug alongside their usual allergy treatments. The study focuses on side effects and how the body processes the drug, not yet on how well it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: stapokibart injection
What this could lead to: If it works, this could point toward a new treatment option for teenagers with seasonal allergies.
What could go wrong: This is a small, early-phase study with only 15 participants, so results may not apply to everyone. The main goal is safety, not yet proof of effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEASONAL ALLERGIC RHINITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

seasonal allergic rhinitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEASONAL ALLERGIC RHINITIS (SAR)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Beijing Tongren Hospital, CMU

Beijing, Beijing Municipality, China

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.